MMIT Reality Check on Ophthalmic Anti-Inflammatory (Apr 2020)

According to our recent payer coverage analysis for ophthalmic anti-inflammatory treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for ophthalmic anti-inflammatory treatments shows that under the pharmacy benefit, almost 57% of the lives under commercial formularies are covered without utilization management restrictions.

Trends: In March 2020, Noveome Biotherapeutics said it will evaluate its ST266, a first-of-its-kind cell-free platform biologic drug that was initially developed for ophthalmology indications, as a potential treatment of severe cytokine storm associated with COVID-19.

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

May 13

MMIT Reality Check on Narcolepsy

Read More
nurse-doing-blood-test
May 6

MMIT Reality Check on Hemophilia B (Factor IX)

Read More
April 29

MMIT Reality Check on Anemia Due to Chronic Kidney Disease

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today